12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Company News  |  Deals

Summit, Bristol-Myers deal

Summit granted Bristol-Myers a license to use Seglin technology to identify and develop drug candidates for up to 10 undisclosed targets. The pharma is...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >